Mr. Björn Rönnerstrand Dr.

Doctor in political science and researcher at the SOM Institute, University Gothenborg Sweden.

Mr. Björn Rönnerstrand is a doctor in political science and researcher at the SOM Institute, University Gothenborg Sweden. He is a member of the steering board of the Centre for Antibiotic Resistance Research, at the University of Gothenburg.  

Rönnerstrand’s research is focused on citizens attitudes towards antibiotics and antibiotic resistance, institutional factors linked to antibiotic use, and international collaboration in the governance of antibiotic resistance in Europe.

Research;  “Governance for collective action in large-scale societal problems”, with a special focus on application in the field of public health. Interpersonal trust and trust in political institutions and authorities.

Current research;  “Governance of collective action”: The case of Antimicrobic Policy in Europe” (2019-2022) with the support of the Swedish Research Council (together with Jon Pierre and Elina Lampi).

“Investigating judicious use of antibiotics – two experimental approaches” (2018-2019) with support from the Centre for Antibiotic Research (CARE) (together with Sverker Jagers, Felicia Robertson, Fredrik Carlsson and Elina Lampi)

Mr. Eero Punkka Dr.

 Director of the Helsinki Biobank

Mr. Eero Punkka is currently Director of the Helsinki Biobank.  Professionally, he has worked in leadership roles of R&D and business development both on the public and private side. He has 20 years of experience in industry ranging from sensor technology to wellness, health and medical products and services. He has originally a research scientist (physics) background from Helsinki University of Technology, VTT Technical Research Center of Finland and Massachusetts Institute of Technology. His passion lies in the digitalization of healthcare and the utilization of health data for the benefit of patients and health professionals.

Mrs.Windi Muziasari PhD.

Resistomap CEO.

Mrs. Windi Muziasari has gained years of experience and the know-how to monitor antibiotic resistance from environmental samples such as wastewater, rivers, lakes, soils and manure using a high-throughput gene profiling during her PhD and PostDoc at the Department of Microbiology, University of Helsinki, Finland. She wanted other researchers at universities, research institutions and hospitals to gain easy access to this technology and that was why she moved from academia to entrepreneurship by founding Resistomap in 2018. Resistomap is the first company in the world to commercialize antibiotic resistance monitoring service in the environment. Headquartered in Helsinki, Resistomap’s mission is to mitigate the spread of antibiotic resistance by providing robust tools for monitoring. Resistomap combines the molecular genetics method and data science to provide a service for antibiotic resistance monitoring comprehensively and fast. Since fully operating in January 2019, Resistomap analyzed over 5000 environmental samples and has served over 170 projects from 34 countries.

Mr. Ville Kainu MD. PhD.

Global Medical Affairs Director, Anti-Infectives Pfizer

Mr. Ville Kainu is currently working in the Global medical affairs team with anti-infectives.

During his 6.5 years Pfizer career Ville had several country positions in medical affairs before joining the global team. During his Pfizer career, AMR has been a central focus area in his work and his activities have included several stakeholder events, as well as blog texts, to address the urgency for actions to battle AMR. Ville is by training and education an MD and his PhD is composed of research in lipidomics.

Mrs. Päivi Sillanaukee MD. PhD. eMBA

Ambassador for Health and Wellbeing
at the Ministry for Foreign Affairs of Finland

Päivi Sillanaukee (MD, PhD, eMBA) is the thematic
Ambassador for Health and Wellbeing at the Ministry for
Foreign Affairs of Finland.
Dr. Sillanaukee is on leave from her duty as the Director General of the Department of Safety, Security and Health of
the Ministry of Social Affairs and Health of Finland. Dr.
Sillanaukee served as the Permanent Secretary of the
Ministry from 2012 to 2019. Between 2008 and 2012, she
was the Director General of the Department for Social and
Health Services at the Ministry. Previously, she was the
Deputy Mayor and Director of Social and Health Services in
the City of Tampere, Finland.
Between 1990 and 2004, she held clinical and managerial
positions in the Pirkanmaa Hospital District and was a
member of the Tampere City Council. Dr. Sillanaukee is a
specialist in public health and management and an honorary
doctor in Medical Faculty from University of Helsinki. She is
promoting and working on policies regarding public health,
social protection, gender equality, innovation and
digitalization in the European Union and at the global level.
She holds a qualification from The Finnish Chamber of
Commerce CBM, as a certified member of the Board.
She has represented Finland in the WHO Executive Board
from May 2018 to May 2021 and served as its first and third
Vice Chair from 2018 to 2020. She is the co-chair of the
Alliance for Health Security Cooperation (AHSC), a member of
the Steering Group of the Global Health Security Agenda
(GHSA), and a member of Health Advisory Board of the UN
Global Pulse Finland Lab. From July 2021 she is a Member of
Board of Directors, HIMSS.

Mr. Pekka Honkanen Prof. em. MD.

 Professor Emiritus of Oulu University and still practizing MD in Terveystalo

Mr. Pekka Honkanen is a Professor Emiritus in General Practice of Oulu University and still a practizing MD in Terveystalo, one of Finlands biggest private Health companies.

Pekka has worked for more than 35 years in several leading positions as Chief Physician in several Health Centres  and Practices. He was a Senior Scientist in the National Public Health Institute and a Senior Lecturer, associate Professor and Professor (until 2016).

Pekka’s other activities were a.o.;

Referee in Scandinavian Journal of Primary Health Care, Clinical Infectious Diseases.

Chairing Good Clinical Practice Guidelines Programs; Lower Respiratory Tract Infections, Throat Infections

Mr. Manuel Freire-Garabal MD. PhD. FRSM  Prof.

Professor of Pharmacology at the School of
Medicine of the University of Santiago de Compostela (USC).

Mr. Manuel Freire-Garabal had executive and advisory responsibilities in several companies and organizations dependent on the USC, European Union,United Nations, and the Spanish government. Dr Freire-Garabal is an expert in drug discovery and development and cutting-edge technologies applied to healthcare and medical education. He has authored more than one hundred scientific articles and twenty books. Freire-Garabal contributed to different media like Times Higher Education, Azad News, UC Berkeley and University of Harvard blogs. Freire-Garabal is a fellow member of the Royal Society of Medicine. He has received more than twenty awards, amongst them, the Sir Anthony Ritossa’s Global Family Office Investment Summit Lifetime Achievement Award, Grand Cross of the Royal Order of Banu Assaf, Golden Medal of the Compostela Group of Universities, Golden Medal of the Association of Former Students and Friends of the USC, and the Royal Academy of Medicine and Surgery of Galicia.

Mrs. Maria Jose Ruiz Alvarez MD.

Scientific officer at the Directorate General for Research and Innovation in Healthcare in the Italian Ministry of Health

Mrs. Maria Jose Ruiz Alvarez Medical, member of the Research Coordination and Support Service (CORI)  in the Italian National Institute of Health (ISS),  works as Scientific officer at the Directorate General for Research and Innovation in Healthcare in the Italian Ministry of Health; and, She is a European Correspondent  (EuCo) for Italy in ECRIN (European Clinical Research Infrastructure Network).

Medical doctor as degree, before joining the CORI, She worked as researcher at the Human immunodeficiency viruses (HIV) Centre (ISS).

She represents It_MoH in several transnational collaborations and international funding programmes , mainly on the field of One Health Antimicrobial Resistance and on Personalised Medicine. As such, She is member of the Management Board of JPIAMR on behalf of the directorate of research and innovation at the Italian Ministry of Health. Working on the different related CSA and ERANet initiatives. At national level, She is working on the National Plan on Antimicrobial Resistance.

 Mrs. Ema Paulino MSc

 President of the Portuguese National Association of Pharmacies

Mrs. Ema Paulino completed her pharmaceutical sciences degree at the University of Lisbon. She also holds a postgraduate degree in leadership from the American Pharmacy Society of the Unified Health System and a postgraduate degree in health management at the Portuguese National School of Public Health.

She is a practising pharmacist at her own community pharmacy in Portugal. She is General Manager of Ezfy, a company that engages community pharmacies in the implementation of Patient Support Programmes.

 She is President of the Portuguese National Association of Pharmacies (ANF) and was a member of the National Board of the Portuguese Pharmaceutical Society (PPS) until June 2021. Ema represents ANF at various international groups and organisations such as the Pharmaceutical Group of the European Union (PGEU) and the International Pharmaceutical Federation (FIP).

Ema is Immediate past-Professional Secretary of FIP, and thus a member of its Executive Committee and Bureau until September 2021. Ema has previously been Chairperson and Project Coordinator of the Young Pharmacists’ Group, a member of the FIP Programme Committee, and Secretary of the Community Pharmacy Section.

Ema is currently in the Board of the Pharmaceutical Care Network Europe (PCNE), and a member of the Board of the International Primary Care Respiratory Group (IPCRG).

She is a member of the Global Health Workforce Network’s Gender Equity Hub, an action-oriented community that aims to connect the dots across contexts and catapult progress in the gender-transformative approaches to health workforce, coordinated by the World Health Organization and Women in Global Health.